| Metric | Value ($ M) | Q1 FY26 |
|---|---|---|
| Revenue | 15.23 | 8.8% |
| Total Income | 15.23 | 8.8% |
| Expenditure | 15.64 | 7.7% |
| PBT | -0.42 | 6.7% |
| Net Profit | -0.43 | 2.3% |
| OPM | -2.69% | 1.08pp |
| NPM | -2.80% | 0.32pp |
| EPS | -0.03 | 0.0% |
Champions Oncology Reports Q1 FY27 Revenue of $15.2 Million, Up 8.8% YoY
11 Sept 2026 · 11 Sept, 2:24 am
Summary
Champions Oncology announced its financial results for the first quarter of fiscal 2027, reporting an 8.8% year-over-year increase in revenue to $15.2 million. The company saw a significant improvement in its oncology services margin, rising to 51% from 43% in the prior year, and its Adjusted EBITDA grew substantially to $671,000 from $59,000. While the company reported a net loss of $426,000, this represents an improvement from the prior year's loss. Management highlighted strong performance driven by improved study execution and conversion in core research services, alongside increased commercial activity for data offerings.
Key Highlights
- 1
Champions Oncology reported revenue of $15.2 million for its first quarter of fiscal 2027, an increase of 8.8% year over year.
- 2
The oncology services margin improved to 51% in Q1 FY27, compared to 43% in the prior-year period.
- 3
Adjusted EBITDA significantly increased to $671,000 in Q1 FY27, from $59,000 in the prior-year period.
- 4
The company reported a net loss of $426,000 for the first quarter of fiscal 2027, an improvement from a net loss of $466,000 in the prior-year period.
- 5
Total costs and operating expenses increased by 7.7% to $15.6 million in Q1 FY27 compared to the prior-year period.
- 6
The company ended the quarter with approximately $4.4 million of cash and no debt.
Management Comments
Robert Brainin
We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins. We are also seeing increased commercial activity around our data offerings as we work to broaden that business across a larger customer base. At the same time, we continued to invest in our commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives. Our focus remains on building sustainable growth across the business while continuing to improve profitability.
David Miller
Revenue increased 8.8% in the first quarter, while oncology services margin improved to 51% from 43% in the prior-year period. Adjusted EBITDA increased to $671,000 from $59,000 in the prior-year quarter, demonstrating the operating leverage in the business as revenue grows. We are continuing to build on the foundation established last year, with a focus on driving revenue growth, maintaining expense discipline and converting that growth into improved profitability.
Informational and educational content only. Not investment advice.